key: cord-0964685-vw1wkq25
authors: Pujadas, Elisabet; Ibeh, Nnaemeka; Hernandez, Matthew M.; Waluszko, Aneta; Sidorenko, Tatyana; Flores, Vanessa; Shiffrin, Biana; Chiu, Numthip; Young‐Francois, Alicia; Nowak, Michael D.; Paniz‐Mondolfi, Alberto E.; Sordillo, Emilia M.; Cordon‐Cardo, Carlos; Houldsworth, Jane; Gitman, Melissa R.
title: Comparison of SARS‐CoV‐2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS‐CoV‐2 test and a laboratory‐developed real‐time RT‐PCR test
date: 2020-05-22
journal: J Med Virol
DOI: 10.1002/jmv.25988
sha: 6fe5e58d8165785269a6bd6b82698c800d1ad972
doc_id: 964685
cord_uid: vw1wkq25

The urgent need to implement and rapidly expand testing for severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection has led to the development of multiple assays. How these tests perform relative to one another is poorly understood. We evaluated the concordance between the Roche Diagnostics cobas 6800 SARS‐CoV‐2 test and a laboratory‐developed test (LDT) real‐time reverse transcription‐polymerase chain reaction based on a modified Centers for Disease Control and Prevention protocol, for the detection of SARS‐CoV‐2 in samples submitted to the Clinical Laboratories of the Mount Sinai Health System. A total of 1006 nasopharyngeal swabs in universal transport medium from persons under investigation were tested for SARS‐CoV‐2 as part of routine clinical care using the cobas SARS‐CoV‐2 test with subsequent evaluation by the LDT. Cycle threshold values were analyzed and interpreted as either positive (“detected” or “presumptive positive”), negative (not detected), inconclusive, or invalid. Statistical analysis was performed using GraphPad Prism 8. The cobas SARS‐CoV‐2 test reported 706 positive and 300 negative results. The LDT reported 640 positive, 323 negative, 34 inconclusive, and 9 invalid results. When excluding inconclusive and invalid results, the overall percent agreement between the two platforms was 95.8%. Cohen's κ coefficient was 0.904 (95% confidence interval, 0.875‐0.933), suggesting almost perfect agreement between both platforms. An overall discordance rate of 4.2% between the two systems may reflect differences in primer sequences, assay limit of detection, or other factors, highlighting the importance of comparing the performance of different testing platforms.

For the cobas SAR-CoV-2 test, an 0.6 mL aliquot of each sample was loaded onto the Roche cobas 6800 where it was combined with the cobas SARS-CoV-2 master mix containing an internal RNA control, primers, and probes targeting the ORF1/a nonstructural region that is specific for SARS-CoV-2 (target 1), as well as the conserved, structural protein envelope E gene that is shared by the Sarbecovirus subgenus were selected from the regions of the virus nucleocapsid gene, with two that were specific for 2019-nCoV (N1 and N2), and also RNase P (RP) as an internal control. The limit of detection (LOD) for this assay was determined to be 1 × 10 3 viral RNA genome equivalents per mL.

The cycle threshold (C t ) values were reported by the cobas SARS-CoV-2 test as either "detected" (targets 1 and 2 detected), "presumptive positive" (target 1 not detected; target 2 detected), or "not detected." The C t values were reported by the LDT as either "detected" (N1 Ct < 38 and N2 Ct < 38), "inconclusive" (N1 Ct ≥ 38 and N2 Ct < 38, or N1 Ct < 38 and N2 Ct ≥ 38), "not detected" (N1 Ct ≥ 38, N2 Ct ≥ 38, and RP Ct < 35) or "invalid" (N1 Ct ≥ 38, N2 Ct ≥ 38, and RP Ct ≥ 35). In the absence of a gold standard, results between the two platforms were compared using overall percent agreement, with two-sided 95% score confidence intervals (CIs) for percent agreement calculated using Clopper-Pearson methodology. 2 To account for agreement due to chance, Cohen's κ coefficient was calculated. 2,3 Statistical analysis was performed using GraphPad Prism version 8 (GraphPad Software, La Jolla, CA).

A total of 1006 NPS samples were tested by the cobas SAR-CoV-2 test and LDT. The cobas SARS-CoV-2 test reported 699 as "detected," 7 as "presumptive positive" (considered as detected) for a total of 706 "detected" and 300 as "not detected". The LDT reported 640 "detected", 323 (Table 1 ).

We compared the agreement between the cobas SARS-CoV-2 test (Roche Molecular Diagnostics) and an LDT based on a modified CDC protocol. There is currently no gold standard for the diagnosis of COVID-19; therefore, sensitivity and specificity could not be calculated. As an alternative, we calculated the overall agreement. We found a high degree of agreement between the two systems whether measured by overall percent agreement and by Cohen's κ. We found Cohen's κ coefficient to be 0.904 (95% CI, 0.875-0.933) indicating excellent agreement between the two tests.

We did detect a discordance rate of 4.2% between the cobas SAR2-CoV-2 test and the LDT. This is consistent with other reports that have found tests targeting the N gene to have a higher LOD than the E gene. 4 We note that of the samples detected by the cobas SARS-CoV-2 test and inconclusive on LDT, the majority Another possibility is that these samples contain low levels of virus, near the limit of detection for the cobas SARS-CoV-2 tests but below the threshold of detection for the LDT.

Similarly, samples with "detected" results by the cobas SARS-CoV-2 test that yielded "not detected" results by the LDT may have been below the limit of detection for the LDT. Examination of C t values in discordant samples revealed a wide range of results, suggesting that while low viral loads in some samples may be contributory, they do not account for all the observed dif-

ferences. An alternative explanation is that differences in the regions of the virus targeted by the two assays play an important role, as has been explored by others. 5 Further studies will be needed to evaluate the performance of diagnostic tests for SARS-CoV-2 infection as this information becomes available, but is beyond the scope of the current paper.

In conclusion, we observed overall excellent agreement between the two tests methods, although our results suggest that cobas SARS-CoV-2 test may have a lower limit of detection than the LDT based on a modified CDC assay. Further studies are needed to compare testing platforms, along with correlation with clinical data to guide testing decisions.

The measurement of observer agreement for categorical data

regulatory-information/search-fda-guidance-documents/statisticalguidance-reporting-results-studies-evaluating-diagnostic-tests-guidanceindustry-and-fda

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays

Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic

Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test

The authors would like to acknowledge Dr. Viviana Simon for here assistance in the development of the LDT.

The authors declare that there are no conflict of interests.

http://orcid.org/0000-0003-4795-7945Melissa R. Gitman http://orcid.org/0000-0002-6960-0763